Correcting NexMed release issued June 11.

LOS ANGELES--(BUSINESS WIRE)--June 12, 1996--Dr. Y. Joseph Mo, chairman, president & chief executive officer, Tuesday announced that NexMed Inc. (NASD:NEXM) resumed trading on the NASD Bulletin Board.

NexMed is in the business of developing and commercializing pharmaceutical and medical proprietary therapeutic and drug delivery systems. Drugs selected are those previously approved by the U.S. Food and Drug Administration (the "FDA") with proven efficacy and safety profiles, with patents expiring or expired, and with proven market record and potential.

NexMed is currently focusing its efforts on: -0-

(i) proprietary topical delivery systems designed to control the drug delivery to patients by enhancing the transdermal delivery of the selected drugs to the active site, thereby allowing drugs to be administered more effectively and more directly, and providing patients with faster relief and lesser side effects;

(ii) the clinical development in the U.S. of NexMed's hand-held, non-invasive, therapeutic patented device, VIRATROL(TM), developed for the treatment of the signs and symptoms of herpes simplex, and the commercialization of VIRATROL(TM) in the Canadian market while seeking approval from the FDA; and,

(iii) proprietary oral delivery systems designed to sustain the delivery of the drugs over a prolonged period of time, thereby allowing drugs to be administered more effectively and consistently, and at a less frequent dosing regimen with improved patient compliance. -0-

NexMed Inc., headquartered in Los Angeles, is a development-stage company concentrating on improved proprietary delivery systems for pharmaceutical and medical products. The company's stock is currently listed on the NASD Bulletin Board under the trading symbol "NEXM".

CONTACT: NexMed Inc., Los Angeles

Vivian Liu, VP, 213/890-0881